Advertisement

Highlights of Investigating Out-of-Specifications Test Results

  • Saji Thomas
  • Kim Huynh-Ba
Chapter
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume XII)

Abstract

Investigating out-of-specification (OOS) results and establishing corrective and preventive action (CAPA) are the critical aspects of the operation of a compliant quality control unit. Investigations are routinely reviewed and scrutinized by the regulatory agencies during cGMP inspection. On September 30, 1998, the FDA announced the availability of the draft guidance for “Investigating Out-of- Specification (OOS) Test Results for Pharmaceutical Production.” This draft has been the subject of some controversies and much discussion. On October 12, 2006, the FDA published the final guidance. This paper summarizes important changes listed in the new version of the guidance and also the implementation of the guidance in the new Quality by Design (QbD) risk-based approach. A review of potential root causes and the effective approach for establishing CAPA are also discussed.

Keywords

Drug Product Standard Operating Procedure Laboratory Error Outlier Test Passing Result 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Reference

  1. Huynh-Ba K (ed) (2008) Handbook of stability testing in pharmaceutical development: regulations, methodologies, and best practices. Springer Science + Business Media, New York, pp 269–275Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  1. 1.Par Pharmaceuticals, Inc.New YorkUSA

Personalised recommendations